Castle Biosciences, Inc. (CSTL) has a negative trailing P/E of -29.5, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 43.1 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -3.39%, forward earnings yield 2.32%. PEG 0.54 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
Overall SharesGrow Score: 58/100 with 2/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2017 | -16.9 | 0.00 | -14.67 | 15.22 | - |
| 2018 | -35.8 | 0.68 | -22.64 | 10.00 | - |
| 2019 | 55.9 | -0.35 | 3.47 | 5.69 | - |
| 2020 | -123.6 | 0.49 | 3.06 | 20.29 | - |
| 2021 | -34.4 | -0.27 | 2.62 | 11.45 | - |
| 2022 | -9.1 | -0.08 | 1.54 | 4.48 | - |
| 2023 | -10.1 | 0.59 | 1.48 | 2.63 | - |
| 2024 | 40.6 | -0.31 | 1.62 | 2.23 | - |
| 2025 | -46.7 | 0.21 | 2.39 | 3.28 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2017 | $-1.26 | $13.75M | $-12.37M | -89.9% |
| 2018 | $-0.60 | $22.79M | $-6.37M | -27.9% |
| 2019 | $-0.21 | $51.87M | $5.28M | 10.2% |
| 2020 | $-0.54 | $62.65M | $-10.28M | -16.4% |
| 2021 | $-1.24 | $94.09M | $-31.29M | -33.3% |
| 2022 | $-2.58 | $137.04M | $-67.14M | -49% |
| 2023 | $-2.14 | $219.79M | $-57.47M | -26.1% |
| 2024 | $0.62 | $332.07M | $18.25M | 5.5% |
| 2025 | $-0.83 | $344.23M | $-24.16M | -7% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-1.17 | $-1.57 – $-0.76 | $345.63M | $343.96M – $348.48M | 6 |
| 2027 | $-0.54 | $-0.55 – $-0.54 | $389.5M | $387.61M – $392.71M | 5 |
| 2028 | $-0.03 | $-0.36 – $0.31 | $433.73M | $431.63M – $437.3M | 5 |
| 2029 | $0.57 | $0.56 – $0.57 | $466.65M | $464.39M – $470.5M | 1 |
| 2030 | $1.02 | $1.01 – $1.03 | $505.55M | $503.1M – $509.72M | 1 |
